Hepatic manifestations of autoimmune rheumatic diseases

This item is provided by the institution :
Hellenic Society of Gastroenterology   

Repository :
Annals of Gastroenterology   

see the original item page
in the repository's web site and access all digital files if the item*



Hepatic manifestations of autoimmune rheumatic diseases (EN)

Soultati, S. Dourakis, Aspasia

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

2007-03-19


Autoimmune rheumatic diseases including Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren’s syndrome, Myositis, Antiphospholipid Syndrome, Behcet’s syndrome, Scleroderma and Vasculitides have been associated with hepatic injury by virtue of multisystem immune and inflammatory involvement. Liver involvement prevalence, significance and specific hepatic pathology vary. After careful exclusion of potentially hepatotoxic drugs or coincident viral hepatitis the question remains whether liver involvement emerges as a manifestation of generalized connective tissue disease or it reflects an underlying primary liver disease sharing an immunological mechanism. Commonly recognised features include mild elevation of liver laboratory values and non specific histological images. Hepatic steatosis, nodular regenerative hyperplasia, portal vein obliteration and portal hypertension, features of primary biliary cirrhosis, vascular disorders, granulomatous reactions and rarely portal fibrosis with abnormal lobular architecture are possible histological findings. Diagnosis can be established on serological, histological and clinical features and after careful exclusion of other possible causes. Association between antirheumatic drugs and hepatic dysfunction has been established in the past. Liver involvement may vary from a mild asymptomatic elevation of liver transaminases or cholestasis parameters to a fulminant hepatitis. A review of the literature to determine the association between primary autoimmune rheumatologic disease and associated hepatic abnormalities and the pharmaceutical interventions that are related to liver damage are presented. Key words: Connective Tissue Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren’s syndrome, Myositis, Giant-Cell Arteritis, Antiphospholipid Syndrome, Behcet’s syndrome, Scleroderma, Vasculitis, Steatosis, Nodular Regenerative Hyperplasia, portal hypertension, Autoimmune Hepatitis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis (EN)


English

Hellenic Society of Gastroenterology (EN)


1792-7463
1108-7471
Annals of Gastroenterology; Volume 18, No 3 (2005) (EN)




*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)